Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Published:2024-07 Issue: Volume: Page:
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Lau George^ORCID,Abou-Alfa Ghassan K.^ORCID,Cheng Ann-Lii,Sukeepaisarnjaroen Wattana^ORCID,Dao Tu Van,Kang Yoon Koo^ORCID,Thungappa Satheesh Chiradoni^ORCID,Kudo Masatoshi^ORCID,Sangro Bruno,Kelley Robin Kate^ORCID,Furuse Junji^ORCID,Park Joong-Won^ORCID,Sunpaweravong Patrapim^ORCID,Fasolo Angelica,Yau Thomas,Kawaoka Tomokazu,Azevedo Sergio,Reig Maria,Assenat Eric,Yarchoan Mark^ORCID,He Aiwu Ruth,Makowsky Mallory,Gupta Charu,Negro Alejandra,Chan Stephen L.^ORCID

Publisher

Elsevier BV

Reference32 articles.

1. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma;Abou-Alfa;NEJM Evid,2022

2. SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma;Sangro;Ann Oncol,2023

3. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study;Kelley;J Clin Oncol,2021

4. US Food and Drug Administration. Imjudo (tremelimumab-actl): highlights of prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289lbl.pdf (accessed 15 August, 2023).

5. European Medicines Agency. Imfinzi: summary of product characteristics. 2023. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf (accessed 15 August, 2023).